Gelesis Holdings, Inc. (GLSH)
| Market Cap | 806.62K |
| Revenue (ttm) | 20.01M |
| Net Income (ttm) | -56.58M |
| Shares Out | 73.33M |
| EPS (ttm) | -0.77 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 28,625 |
| Open | 0.0156 |
| Previous Close | n/a |
| Day's Range | 0.0111 - 0.0180 |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About GLSH
Gelesis Holdings, Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. It also offers PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, the company develops GS200 for weight loss in prediabetes and type 2 diabetes; and GS500 for functional constipation. Further, it develops pre-clinical product GS300 for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. Gelesis Holdings, Inc. was incorporate... [Read more]
Financial Performance
In 2022, GLSH's revenue was $25.77 million, an increase of 130.37% compared to the previous year's $11.19 million. Losses were -$95.06 million, -49.40% less than in 2021.
Financial StatementsNews
NYSE to Suspend Trading Immediately in Gelesis Holdings, Inc. (GLS) and Commence Delisting Proceedings
NEW YORK--(BUSINESS WIRE)--The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of G...
Gelesis Reports Fourth Quarter and Full Year 2022 Results
BOSTON--(BUSINESS WIRE)---- $GLS #earnings--Gelesis Holdings, Inc. (NYSE: GLS) (“Gelesis” or the “Company”), the maker of Plenity for weight management, today reported financial results for the year e...
Gelesis to Participate in the 25th Annual ICR Conference
BOSTON--(BUSINESS WIRE)--Gelesis (NYSE: GLS), the maker of Plenity for weight management, today announced that the Company will participate in the 25th Annual ICR Conference in Orlando, Florida on M...
NYSE to Suspend Trading Immediately in Warrants of Gelesis Holdings, Inc. (GLS WS) and Commence Delisting Proceedings
NEW YORK--(BUSINESS WIRE)--The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the warrants of Gel...
Gelesis Reports Upcoming Participation in Wolfe Research's Annual Consumer Growth Conference
BOSTON--(BUSINESS WIRE)--Gelesis Holdings, Inc. (NYSE: GLS) (“Gelesis” or the “Company”), the maker of Plenity for weight management, today announced that its Chief Operating & Commercial Officer, D...
Gelesis Receives Notice of NYSE Market Capitalization Listing Rule Non-Compliance
BOSTON--(BUSINESS WIRE)--Gelesis Holdings Inc. (NYSE: GLS) (“Gelesis” or the “Company”) today noted that on November 16, 2022, the Company received a notification letter (the “Notice”) from the New ...
Gelesis Reports Third Quarter 2022 Results
BOSTON--(BUSINESS WIRE)--Gelesis Holdings, Inc. (NYSE: GLS) (“Gelesis” or the “Company”), the maker of Plenity for weight management, today reported financial results for the third quarter of 2022. ...
Gelesis to Report Third Quarter 2022 Financial Results on November 14, 2022
BOSTON--(BUSINESS WIRE)--Gelesis Holdings, Inc. (NYSE:GLS) (“Gelesis” or the “Company”), the maker of Plenity® for weight management, today announced that the Company will report financial results for...
Gelesis Receives Notice of NYSE Trading Share Price Listing Rule Non-Compliance
BOSTON--(BUSINESS WIRE)--Gelesis Holdings Inc. (NYSE: GLS) (“Gelesis” or the “Company”) today noted that the Company received a notification letter from the New York Stock Exchange (the “NYSE”) advisi...
Data Presented at Obesity Week Demonstrate that Gelesis Investigational Clinical-Stage Oral Superabsorbent Hydrogel Gel-B Preferentially Enhances the Growth of Akkermansia muciniphila in Preclinical Models Compared to Prebiotics
BOSTON--(BUSINESS WIRE)--Gelesis Holdings Inc. (NYSE: GLS) (“Gelesis” or the “Company”) the maker of Plenity for weight management, today released new data at Obesity Week in San Diego.
Dr. Frank Greenway to Present Data from the LIGHT-UP Study with Gelesis' Oral Hydrogel Treatment GS200 at Obesity Week
BOSTON--(BUSINESS WIRE)--Gelesis Holdings Inc. (NYSE: GLS) (“Gelesis” or the “Company”) the maker of Plenity for weight management, today announced Dr. Frank Greenway will give an oral presentation at...
Gelesis to Participate in the Jefferies Virtual Fitness & Wellness Summit
BOSTON--(BUSINESS WIRE)--Gelesis Holdings Inc. (NYSE: GLS) (“Gelesis” or the “Company”), the maker of Plenity for weight management, today announced that Yishai Zohar, Founder and Chief Executive Offi...
Clinical Data from the LIGHT-UP Study Presented at the International Congress of Endocrinology Suggests New Gelesis Oral Hydrogel May Improve Insulin Sensitivity and Favorably Impact Metabolic Syndrome
BOSTON--(BUSINESS WIRE)--Gelesis Holdings Inc. (NYSE: GLS) (“Gelesis” or the “Company”) the maker of Plenity for weight management, today released a poster presentation at the International Congress o...
Gelesis to Participate in Fireside Chat with IPO Edge Today at 2:00 PM ET
BOSTON--(BUSINESS WIRE)--Gelesis Holdings Inc. (NYSE: GLS) (“Gelesis” or the “Company”) the maker of Plenity for weight management, today announced that the Company is participating in a fireside chat...
Gelesis Reports Second Quarter 2022 Results
BOSTON--(BUSINESS WIRE)--Gelesis (NYSE: GLS), the maker of Plenity for weight management, today reported financial results for the second quarter of 2022. “We are seeing both consumers and clinicians ...
Gelesis to Report Second Quarter 2022 Financial Results on August 15, 2022
BOSTON--(BUSINESS WIRE)--Gelesis Holdings, Inc. (NYSE:GLS) (“Gelesis” or the “Company”), the maker of Plenity® for weight management, today announced that the Company will report financial results for...
Gelesis Announces Additional $15 Million Pre-Order for Plenity®, Bringing Total Pre-Paid Orders from Ro for Plenity to $55 Million
BOSTON--(BUSINESS WIRE)--Gelesis announced today that Ro, a leading and rapidly growing U.S. direct-to-patient healthcare company, has placed a $15 million pre-paid order for the company's commercial ...
Over the Past Decade, Person-First Language Was Used in Only About Half of Diabetes-Focused Articles and Fewer than 1% of Obesity Articles, Finds New Study
BOSTON--(BUSINESS WIRE)--Gelesis (NYSE: GLS), the maker of Plenity for weight management, presented new findings about the role of language in obesity and diabetes scientific literature at the America...
Microbiota Transplantation Demonstrates How Gut Bacteria Contributes to Weight Loss and Beneficial Metabolic Effects with Gelesis' Proprietary Hydrogel
BOSTON--(BUSINESS WIRE)--Gelesis (NYSE: GLS), the maker of Plenity for weight management, presented new preclinical data showing weight loss and additional metabolic benefits in mice receiving a micro...
Gelesis to Participate in Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--Gelesis (NYSE: GLS), the maker of Plenity for weight management, today announced that Yishai Zohar, Founder and Chief Executive Officer, Elliot Maltz, Chief Financial Officer,...
Gelesis Reports First Quarter 2022 Results
BOSTON--(BUSINESS WIRE)--Gelesis (NYSE: GLS), the maker of Plenity for weight management, today reported financial results for the first quarter of 2022. “We saw all-time highs of people seeking and s...
Gelesis to Report First Quarter 2022 Financial Results on May 12, 2022
BOSTON--(BUSINESS WIRE)--Gelesis (NYSE: GLS), the maker of Plenity® for weight management, today announced that the Company will report financial results for the First Quarter ended March 31, 2022, on...
Clinical Data Presented at the European Congress on Obesity 2022 Demonstrates Weight Loss With GS200 in Adults With Prediabetes and Type 2 Diabetes
BOSTON--(BUSINESS WIRE)--Gelesis (NYSE: GLS), a consumer-focused biotherapeutics company and the maker of Plenity®, today presented results from the LIGHT-UP clinical trial for adults with overweight ...
Gelesis' Proprietary Superabsorbent Hydrogel Induced Beneficial Changes to the Gut Microbiota and Expanded Akkermansia, a Bacterial Species Associated with Gut Health and Weight Loss, in New Study
BOSTON--(BUSINESS WIRE)--Gelesis (NYSE: GLS), a consumer-focused biotherapeutics company and the maker of Plenity®, released today a poster presentation at the World of Microbiome annual meeting in Vi...
Gelesis® Reports Fiscal Year 2021 Results and Fiscal Year 2022 Financial Outlook
BOSTON--(BUSINESS WIRE)---- $GLS #earnings--Gelesis (NYSE: GLS), the maker of Plenity for weight management, today reported financial results for its fiscal year ended December 31, 2021. Yishai Zohar,...